文献速递呼吸道感染

关注成人社区获得性肺炎病原学新演变趋势

[Pay attention to new evolution trends in the etiology of community-acquired pneumonia in adults].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2024-01-01

近二三十年来,新发再发感染病、分子检测技术进步、抗生素耐药及人群免疫状态变化等因素导致成人社区获得性肺炎(CAP)病原学发生新演变。肺炎链球菌虽仍常见但已非首位,病毒挑战增加,肺炎支原体地位存争议,多重耐药革兰阴性菌受关注,共感染报道混乱。病原学演变呈多样化、地方化趋势,给大国统一指南制定带来困难,本文对制定地方性CAP诊治指导意见提出建议。

要点

  • 肺炎链球菌仍常见但中国和美国已不居首位。
  • 病毒在成人CAP病原中地位上升,挑战增加。
  • 肺炎支原体经验性常规覆盖除重症外证据不支持。

核心结论

  • 成人CAP病原学呈现多样化、地方化演变趋势,统一指南制定困难。
  • 建议根据本地病原学数据制定地方性CAP诊治指导意见。

研究设计与样本

  • 本文为综述性文章,汇总近二三十年成人CAP病原学演变相关研究。
  • 引用中国多中心研究、全国监测、系统综述及CARSS等数据。

主要发现

  • 中国21世纪初2项多中心研究显示肺炎链球菌占成人CAP病原10.3%和12.0%,居第二位。
  • 2014-2019年中国九城市研究显示肺炎链球菌总体检出率7.43%,居第六位,各城市排名第三至第七不等。
  • 2009-2019年中国成人肺炎病毒感染阳性率20.5%,病毒排名第二,美国CDC研究中病毒排名第一。
  • 中国大陆肺炎支原体在CAP病原中排名第一(11.05%),但地区差异显著。
  • 中国文献系统综述显示肺炎克雷伯菌占成人CAP 8.12%(第五位),铜绿假单胞菌占4.7%(第九位)。

关键数值与推荐

  • 肺炎链球菌在中国和美国已不居CAP首位。
  • 病毒在中国成人肺炎中阳性率20.5%,排名第二;美国排名第一。
  • 肺炎支原体在中国大陆CAP病原中排名第一(11.05%),但地区差异大。
  • 除重症病例外,现有证据不支持经验性治疗常规覆盖肺炎支原体。
  • 在肺炎支原体高流行区,轻中度CAP是否覆盖非典型病原体应基于本地数据个体化决策。

临床怎么用

  • 临床应关注CAP病原学地方性差异,参考本地数据指导经验性治疗。
  • 轻中度CAP不推荐常规经验性覆盖肺炎支原体,除非重症或本地高流行且个体化评估。
  • 多重耐药革兰阴性菌感染风险高时,可用本地验证的风险因素评分系统预测耐药谱。
  • 共感染诊断需规范定义和检测技术,区分共检测与共感染,避免抗生素过度使用。

局限性

  • 共感染定义和概念不一致,检测技术选择存在混乱。
  • 部分共感染报道缺乏病原学证据,COVID-19中曾将「有效抗生素治疗」作为诊断标准之一。
  • CAP病原学地区差异大,难以制定统一指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past two to three decades, the emergence and re-emergence of new infectious diseases, advances in molecular detection techniques of pathogens, antibiotic resistance, changes in population lifestyle and immune status (including vaccination), and other factors have led to new evolutions in the etiology of community-acquired pneumonia (CAP). (1) Although Streptococcus pneumoniae remains a common pathogen of CAP, it is no longer the leading cause in China and the United States. According to the results of 2 multicenter studies in China in the early 21st century, Streptococcus pneumoniae accounted for 10.3% and 12.0% of adult CAP pathogens, respectively, ranking second. A study on key pathogens of adult CAP in nine cities in mainland China from 2014 to 2019 using real-time quantitative PCR and conventional culture on respiratory and blood specimens showed an overall prevalence of Streptococcus pneumoniae of 7.43%, ranking sixth. However, its ranking varied from third to seventh among the nine cities. (2) Challenges and concerns about viruses have increased. National surveillance of acute respiratory tract infections and epidemiology in China from 2009 to 2019 indicated that the positivity rates for viral infections in adult pneumonia was 20.5%. These rates were similar to the results of the CDC's CAP pathogen study in the United States, although the rankings were different (viruses ranked second in China and first in the United States). Over the past 20 years, the emergence of new viral respiratory infections caused by mutant strains or zoonotic strains has significantly increased the challenges and threats posed by viral respiratory infections. (3) The role of Mycoplasma pneumoniae (M pneumoniae) in adult CAP and the need for routine empirical antibiotic coverage are controversial. In addition to the influence of epidemic cycles, the prevalence of M pneumoniae is influenced by factors such as age, season, study design, and detection methods, and geographical distribution is also an important influencing factor. Although M. pneumoniae ranks first among CAP pathogens in mainland China (11.05%), there are significant regional differences. In Beijing, Xi'an, and Changchun M. pneumoniae ranks first, while in Harbin, Nanjing, and Fuzhou it ranks second to sixth. In Wuhan, Shenzhen, and Chengdu M. pneumoniae ranks after the tenth position. Available evidence supports the notion that routine coverage of M. pneumoniae is not necessary for empirical treatment of CAP, except in severe cases. In regions with a high prevalence of M. pneumoniae, the decision to cover atypical pathogens in patients with mild to moderate CAP should be based on local data and individualized. (4) CAP caused by multidrug-resistant bacteria, especially multidrug-resistant Gram-negative bacilli (GNB), has become a concern. According to a systematic review of Chinese literature, Klebsiella pneumoniae accounted for 8.12% of adult CAP patients, ranking fifth, and Pseudomonas aeruginosa accounted for 4.7% (ninth). The China Antimicrobial Resistance Surveillance System (CARSS) reported an average resistance rate of 27.7% for Klebsiella pneumoniae to third-generation cephalosporins and a resistance rate of 10.0% to carbapenems in 2021. The average resistance rate of Pseudomonas aeruginosa to carbapenems was 16.6%. Early empirical treatment should consider predicting the resistance profile using a "locally validated risk factor" scoring system. (5) Co-infections are common but under-reported. The development of non-culture detection techniques over the past 40 years has significantly increased the detection rate of respiratory pathogens, especially viruses, leading to an increasing number of reports of bacterial-viral co-infections in CAP. It has been reported that co-infections account for 39% of severe CAP cases on ventilators in the ICU. Currently, there is inconsistency and confusion regarding the definition and concept of co-infection, the choice of detection techniques, and the differentiation between co-detection and co-infection. Many reports of co-infections in COVID-19 lacked pathogenic evidence, and some even listed "effective antibiotic treatment" as one of the diagnostic criteria for viral-bacterial co-infections, suggesting to some extent an overuse of antibiotics in COVID-19. Due to the diverse etiological spectrum of CAP between regions in the recent years, it is challenging to develop unified guidelines for the management of CAP in large countries. This article provides recommendations for the development of local guidelines for the diagnosis and treatment of CAP. 近二三十年来新发和再发感(传)染病频现、病原学分子检测技术进步、抗生素耐药、人群生活方式和免疫状态变化(包括疫苗接种)等原因,致CAP病原学发生新的演变。(1)肺炎链球菌虽然仍是CAP的常见病原体,但在中国和美国已不居首位。(2)病毒的挑战与困扰增加。(3)肺炎支原体在成人CAP的地位和经验性抗菌治疗常规覆盖的观点存在争议。(4)CAP多耐药菌特别多重耐药GNB感染受到关注。(5)共感染常见而报道混乱。由于CAP病原学演变呈现出多样化、地方化的趋势,给大国制订统一指南带来困难,本文对制订地方性CAP诊治指导意见提出建议。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. He. [Pay attention to new evolution trends in the etiology of community-acquired pneumonia in adults]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38858211. doi:10.3760/cma.j.cn112147-20231024-00264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。